Close Menu

NEW YORK (GenomeWeb) – MolecularMD said this week that it has validated Thermo Fisher Scientific’s Oncomine Tumor Mutation Load Assay for clinical research trials for immunotherapy drug development. The assay interrogates 409 cancer-related genes and correlates well with exome mutation counts. MolecularMD has also developed an alternative workflow and quality control method to address deamination errors, which may result in inflated tumor mutational burden (TMB).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.